Search Results for "Upsher Smith Executives"
Original Source: Upsher-Smith Laboratories, Inc.
Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded, branded-generic and generic pharmaceuticals. Upsher-Smith has a particular focus on providing therapies to assist people suffering from central nervous system diseases (including epilepsy, Parkinson's disease and Alzheimer's disease) and also produces products r...
Matching Channels
CurrentPartnering was established in 2007 to offer an objective and informal business tool for business development executives, providing an opportunity for the dissemination of the latest trends in...
Matching News
Coming In Thursday's "The Pink Sheet" DAILY - Upsher-Smith Makes $347M Offer For Proximagen
Already holding a 16% equity interest in U.K. biotech Proximagen, Upsher-Smith announced an agreement June 13 to buy out the company about $347 million in cash, along with contingent-value rights pegg...
Upsher-Smith to acquire U.K.-based Proximagen
Upsher-Smith Laboratories, a privately-owned specialty pharmaceutical company of Maple Grove, Minn., has agreed to acquire Proximagen Group, a European biotech focused on the development and commercia...
Upsher-Smith Introduces Newly Redesigned Corporate Website
MAPLE GROVE, Minn., May 20, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., a specialty pharmaceutical company committed to the development of new treatments for diseases of the central ner...
Upsher-Smith to Pay up to $555 Million for Proximagen
U.S. drugmaker Upsher-Smith Laboratories is to buy British group Proximagen for 223 million pounds ($347 million) plus further payments potentially worth up to 134 million based on the success of two...
Upsher-Smith acquires Proximagen for $553 million
USL Pharma International U.K. Ltd., a wholly-owned subsidiary of Upsher-Smith Laboratories has agreed a recommended offer for European biotechnology company Proximagen Group PLC which values the compa...
Upsher-Smith to acquire Proximagen
Specialty pharma Upsher-Smith Laboratories Inc. (Maple Grove, Minn.) will acquire the 84% of Proximagen Group plc (LSE:PRX) it does not already own for 320p per share in cash. The price, which values...
USA's GPhA files Amicus Brief in Upsher-Smith vs Louisiana Wholesale Drug Co, et al
The USA's Generic Pharmaceutical Association (GPhA) says that it has filed an Amicus Brief ("friend of the court" or a person with strong interest in or views on the subject matter of an action, but n...
Upsher-Smith's price for Proximagen could reach $554.7M
Upsher-Smith Laboratories agreed to purchase the remaining shares of U.K. biotech firm Proximagen for about $347 million. -More-
Matching PubMed Articles
Self-Healing Microencapsulation of Biomacromolecules without Organic Solvents.
Capture and seal off all exits! Biomacromolecules are routinely microcapsulated in poly(lactic-co-glycolic acid) (PLGA) in multiple complex steps that are deleterious to the biomacromolecule. In contr...
Perspectives on executive relationships: influence.
This department, sponsored by AONE, presents information to assist nurse leaders in shaping the future of healthcare through creative and innovative leadership. The strategic priorities of AONE anchor...
How to build a strong résumé and land a new job.
BACKGROUND: Evaluation of anterior chamber depth (ACD) can potentially identify those patients at risk of angle-closure glaucoma. We aimed to: compare van Herick's limbal chamber depth (LCDvh) grades...
